Biomed Central Ltd

SHERPA: Unknown

People

  1. Motzer
    Motzer
  2. Voss
    Voss
  3. Autio
    Autio
  4. Rosenberg
    Rosenberg
  5. Shah
    Shah
  6. Carlo
    Carlo
  7. Kotecha
    Kotecha
  8. Solit
    Solit
  9. Feldman
    Feldman
  10. Iyer
    Iyer

Groups

  1. Department of Medicine (81)
  2. Genitourinary Oncology Service (81)
  3. Solid Tumor Oncology Division (81)
  4. Weinberg Fellows (14)
  5. GSK Faculty (13)
  6. Hematologic Malignancies, Division of (12)
  7. Human Oncology and Pathogenesis Program (10)
  8. Epidemiology and Biostatistics (9)
  9. Biostatistics Service (7)
  10. Survivorship Research (7)
Search Within
  1. "Genitourinary Oncology Service"
Formats
  1. Journal Article (51)
  2. Meeting Abstract (27)
  3. Guidelines (2)
  4. Review (1)
Groups
  1. Department of Medicine (81)
  2. Genitourinary Oncology Service (81)
  3. Solid Tumor Oncology Division (81)
  4. Weinberg Fellows (14)
  5. GSK Faculty (13)
  6. Hematologic Malignancies, Division of (12)

More Groups

People
  1. Robert Motzer (22)
  2. Martin Voss (15)
  3. Karen Autio (11)
  4. Jonathan Rosenberg (8)
  5. Neil Shah (7)
  6. Chung-Han Lee (5)

More People

Years
  1. 2024 (2)
  2. 2023 (5)
  3. 2022 (13)
  4. 2021 (14)
  5. 2020 (7)
  6. 2019 (4)

More Years

Publications
  1. Journal for ImmunoTherapy of Cancer (53)
  2. BMC Cancer (8)
  3. Genome Medicine (4)
  4. Journal of Hematology & Oncology (3)
  5. Journal of Translational Medicine (3)
  6. Breast Cancer Research (2)

More Publications

Results (81)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Treatment-free survival and partitioned survival analysis of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib: 5-year update of CheckMate 214
    Journal Article

    Mantia, C. M.; Jegede, O. A.; Plimack, E. R.; Powles, T.; Motzer, R. J.; Tannir, N. M.; Lee, C. H.; Tomita, Y.; Voss, M. H.; Choueiri, T. K.; more...
    Journal for ImmunoTherapy of Cancer (2024)

    Fulltext@MSK | Save
  • A randomized, open-label, phase 3 trial of pembrolizumab plus epacadostat versus sunitinib or pazopanib as first-line treatment for metastatic renal cell carcinoma (KEYNOTE-679/ECHO-302)
    Journal Article

    Lara, P. N.; Villanueva, L.; Ibanez, C.; Erman, M.; Lee, J. L.; Heinrich, D.; Lipatov, O. N.; Gedye, C.; Gokmen, E.; Acevedo, A.; more...
    BMC Cancer (2024)

    Fulltext@MSK | Save
  • Evaluating residual tumor after neoadjuvant chemotherapy for muscle-invasive urothelial bladder cancer: Diagnostic performance and outcomes using biparametric vs. multiparametric MRI
    Journal Article

    Woo, S.; Becker, A. S.; Das, J. P.; Ghafoor, S.; Arita, Y.; Benfante, N.; Gangai, N.; Teo, M. Y.; Goh, A. C.; Vargas, H. A.
    Cancer Imaging (2023)

    Fulltext@MSK | Save
  • TCR-engaging scaffolds selectively expand antigen-specific T-cells with a favorable phenotype for adoptive cell therapy
    Journal Article

    Tvingsholm, S. A.; Frej, M. S.; Rafa, V. M.; Hansen, U. K.; Ormhøj, M.; Tyron, A.; Jensen, A. W. P.; Kadivar, M.; Bentzen, A. K.; Munk, K. K.; more...
    Journal for ImmunoTherapy of Cancer (2023)

    Fulltext@MSK | Save
  • First-in-human, phase 1 study of PF-06753512, a vaccine-based immunotherapy regimen (VBIR), in non-metastatic hormone-sensitive biochemical recurrence and metastatic castration-resistant prostate cancer (mCRPC)
    Journal Article

    Autio, K. A.; Higano, C. S.; Nordquist, L.; Appleman, L. J.; Zhang, T.; Zhu, X. H.; Babiker, H.; Vogelzang, N. J.; Prasad, S. M.; Schweizer, M. T.; more...
    Journal for ImmunoTherapy of Cancer (2023)

    Fulltext@MSK | Save
  • First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1)
    Journal Article

    Postel-Vinay, S.; Lam, V. K.; Ros, W.; Bauer, T. M.; Hansen, A. R.; Cho, D. C.; Stephen Hodi, F.; Schellens, J. H. M.; Litton, J. K.; Aspeslagh, S.; more...
    Journal for ImmunoTherapy of Cancer (2023)

    Fulltext@MSK | Save
  • Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous Coxsackievirus A21 (V937), with or without pembrolizumab, in patients with advanced solid tumors
    Journal Article

    Rudin, C. M.; Pandha, H. S.; Zibelman, M.; Akerley, W. L.; Harrington, K. J.; Day, D.; Hill, A. G.; O'Day, S. J.; Clay, T. D.; Wright, G. M.; more...
    Journal for ImmunoTherapy of Cancer (2023)

    Fulltext@MSK | Save
  • Prediction of best response for NSCLC patients receiving immunotherapy by machine learning models
    Meeting Abstract

    Zhang, Y.; Gupta, S.; Belouali, A.; Lev-Ari, S.; Shah, N.; Krishnamurthy, K.; Serzan, M.; Alaoui, A.; McGarvey, P.; Atkins, M.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • A multicohort phase 1b study (STELLAR-002) of XL092 in combination with immunotherapy in patients with advanced solid tumors
    Meeting Abstract

    McGregor, B.; Choueiri, T.; Shah, N.; Bajaj, A.; Chahoud, J.; O'Neil, B.; Michalski, J.; Garmezy, B.; Jin, L.; Aziz, U.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • Initial results from a phase 1a/b study of IK-175, an oral AHR inhibitor, as a single agent and in combination with nivolumab in patients with advanced solid tumors and urothelial carcinoma
    Meeting Abstract

    Aggen, D.; McKean, M.; Lakhani, N.; Bashir, B.; Hoffman-Censits, J.; Alhalabi, O.; Guancial, E.; Bowman, I.; Tan, A.; Lingaraj, T.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save